| Ambrish K Gupta, MD | |
|
611 S Carlin Springs Rd Ste 504, Arlington, VA 22204-1088 | |
| (703) 998-6666 | |
| (703) 578-0700 |
| Full Name | Ambrish K Gupta |
|---|---|
| Gender | Male |
| Speciality | Cardiovascular Disease (cardiology) |
| Experience | 44 Years |
| Location | 611 S Carlin Springs Rd Ste 504, Arlington, Virginia |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1518991892 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RC0000X | Internal Medicine - Cardiovascular Disease | 0101035666 (Virginia) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Virginia Hospital Center | Arlington, VA | Hospital |
| Inova Alexandria Hospital | Alexandria, VA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Alexandria Health Care Center, Pllc | 3072662527 | 3 |
| Ivyrehab Sept, Llc | 7911990908 | 1137 |
| Mclean Medical Center And Urgent Care Llc | 8325210818 | 2 |
| Medical Associates Of Northern Va Inc | 4587609029 | 2 |
News Archive
Emmaus Medical, Inc., a pharmaceutical company developing a new treatment for sickle cell disease, and subsidiary of Emmaus Life Sciences, Inc., announced today that its investigational L-glutamine treatment for sickle cell disease has received a positive opinion recommending orphan medicinal product designation by the European Medicines Agency's (EMA) Committee for Orphan Medicinal Products (COMP). The designation allows Emmaus ten years of marketing exclusivity in EU member countries after the product obtains marketing authorization, as well as streamlined regulatory review processes and registration and other fee reductions.
A new biological study by the University of Stirling has found that exposure to infections in early life does not have long-lasting consequences for later-life survival and reproduction.
PURE Bioscience announced that it has expanded its business strategy through an alliance with the Dallas-based sales and marketing team Richmont Sciences, LLC, which will begin actively selling PURE's revolutionary new antibacterial, antiviral and antifungal hard surface disinfectant and its active ingredient.
Investigators at Duke Medicine and the University of California, San Francisco have been selected to oversee a nationwide research program on antibacterial resistance, which includes a focus on the growing unmet challenges associated with methicillin-resistant Staphylococcus aureus and E. coli.
Spacelabs Healthcare is pleased to announce the U.S. launch of Sentinel, a sophisticated Cardiology Information Management Systems (CIMS), that will facilitate analysis and reporting while also improving efficiency and eliminating errors.
› Verified 3 days ago
| Entity Name | Medical Associates Of Northern Va Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1942230826 PECOS PAC ID: 4587609029 Enrollment ID: O20050624000202 |
News Archive
Emmaus Medical, Inc., a pharmaceutical company developing a new treatment for sickle cell disease, and subsidiary of Emmaus Life Sciences, Inc., announced today that its investigational L-glutamine treatment for sickle cell disease has received a positive opinion recommending orphan medicinal product designation by the European Medicines Agency's (EMA) Committee for Orphan Medicinal Products (COMP). The designation allows Emmaus ten years of marketing exclusivity in EU member countries after the product obtains marketing authorization, as well as streamlined regulatory review processes and registration and other fee reductions.
A new biological study by the University of Stirling has found that exposure to infections in early life does not have long-lasting consequences for later-life survival and reproduction.
PURE Bioscience announced that it has expanded its business strategy through an alliance with the Dallas-based sales and marketing team Richmont Sciences, LLC, which will begin actively selling PURE's revolutionary new antibacterial, antiviral and antifungal hard surface disinfectant and its active ingredient.
Investigators at Duke Medicine and the University of California, San Francisco have been selected to oversee a nationwide research program on antibacterial resistance, which includes a focus on the growing unmet challenges associated with methicillin-resistant Staphylococcus aureus and E. coli.
Spacelabs Healthcare is pleased to announce the U.S. launch of Sentinel, a sophisticated Cardiology Information Management Systems (CIMS), that will facilitate analysis and reporting while also improving efficiency and eliminating errors.
› Verified 3 days ago
| Entity Name | Alexandria Health Care Center, Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1922131887 PECOS PAC ID: 3072662527 Enrollment ID: O20090513000117 |
News Archive
Emmaus Medical, Inc., a pharmaceutical company developing a new treatment for sickle cell disease, and subsidiary of Emmaus Life Sciences, Inc., announced today that its investigational L-glutamine treatment for sickle cell disease has received a positive opinion recommending orphan medicinal product designation by the European Medicines Agency's (EMA) Committee for Orphan Medicinal Products (COMP). The designation allows Emmaus ten years of marketing exclusivity in EU member countries after the product obtains marketing authorization, as well as streamlined regulatory review processes and registration and other fee reductions.
A new biological study by the University of Stirling has found that exposure to infections in early life does not have long-lasting consequences for later-life survival and reproduction.
PURE Bioscience announced that it has expanded its business strategy through an alliance with the Dallas-based sales and marketing team Richmont Sciences, LLC, which will begin actively selling PURE's revolutionary new antibacterial, antiviral and antifungal hard surface disinfectant and its active ingredient.
Investigators at Duke Medicine and the University of California, San Francisco have been selected to oversee a nationwide research program on antibacterial resistance, which includes a focus on the growing unmet challenges associated with methicillin-resistant Staphylococcus aureus and E. coli.
Spacelabs Healthcare is pleased to announce the U.S. launch of Sentinel, a sophisticated Cardiology Information Management Systems (CIMS), that will facilitate analysis and reporting while also improving efficiency and eliminating errors.
› Verified 3 days ago
| Entity Name | Mclean Medical Center And Urgent Care Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1447539325 PECOS PAC ID: 8325210818 Enrollment ID: O20111005000305 |
News Archive
Emmaus Medical, Inc., a pharmaceutical company developing a new treatment for sickle cell disease, and subsidiary of Emmaus Life Sciences, Inc., announced today that its investigational L-glutamine treatment for sickle cell disease has received a positive opinion recommending orphan medicinal product designation by the European Medicines Agency's (EMA) Committee for Orphan Medicinal Products (COMP). The designation allows Emmaus ten years of marketing exclusivity in EU member countries after the product obtains marketing authorization, as well as streamlined regulatory review processes and registration and other fee reductions.
A new biological study by the University of Stirling has found that exposure to infections in early life does not have long-lasting consequences for later-life survival and reproduction.
PURE Bioscience announced that it has expanded its business strategy through an alliance with the Dallas-based sales and marketing team Richmont Sciences, LLC, which will begin actively selling PURE's revolutionary new antibacterial, antiviral and antifungal hard surface disinfectant and its active ingredient.
Investigators at Duke Medicine and the University of California, San Francisco have been selected to oversee a nationwide research program on antibacterial resistance, which includes a focus on the growing unmet challenges associated with methicillin-resistant Staphylococcus aureus and E. coli.
Spacelabs Healthcare is pleased to announce the U.S. launch of Sentinel, a sophisticated Cardiology Information Management Systems (CIMS), that will facilitate analysis and reporting while also improving efficiency and eliminating errors.
› Verified 3 days ago
| Entity Name | Fairfax Urgent Care Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1376823237 PECOS PAC ID: 5991978215 Enrollment ID: O20111102000584 |
News Archive
Emmaus Medical, Inc., a pharmaceutical company developing a new treatment for sickle cell disease, and subsidiary of Emmaus Life Sciences, Inc., announced today that its investigational L-glutamine treatment for sickle cell disease has received a positive opinion recommending orphan medicinal product designation by the European Medicines Agency's (EMA) Committee for Orphan Medicinal Products (COMP). The designation allows Emmaus ten years of marketing exclusivity in EU member countries after the product obtains marketing authorization, as well as streamlined regulatory review processes and registration and other fee reductions.
A new biological study by the University of Stirling has found that exposure to infections in early life does not have long-lasting consequences for later-life survival and reproduction.
PURE Bioscience announced that it has expanded its business strategy through an alliance with the Dallas-based sales and marketing team Richmont Sciences, LLC, which will begin actively selling PURE's revolutionary new antibacterial, antiviral and antifungal hard surface disinfectant and its active ingredient.
Investigators at Duke Medicine and the University of California, San Francisco have been selected to oversee a nationwide research program on antibacterial resistance, which includes a focus on the growing unmet challenges associated with methicillin-resistant Staphylococcus aureus and E. coli.
Spacelabs Healthcare is pleased to announce the U.S. launch of Sentinel, a sophisticated Cardiology Information Management Systems (CIMS), that will facilitate analysis and reporting while also improving efficiency and eliminating errors.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Ambrish K Gupta, MD 611 S Carlin Springs Rd Ste 504, Arlington, VA 22204-1088 Ph: (703) 998-6666 | Ambrish K Gupta, MD 611 S Carlin Springs Rd Ste 504, Arlington, VA 22204-1088 Ph: (703) 998-6666 |
News Archive
Emmaus Medical, Inc., a pharmaceutical company developing a new treatment for sickle cell disease, and subsidiary of Emmaus Life Sciences, Inc., announced today that its investigational L-glutamine treatment for sickle cell disease has received a positive opinion recommending orphan medicinal product designation by the European Medicines Agency's (EMA) Committee for Orphan Medicinal Products (COMP). The designation allows Emmaus ten years of marketing exclusivity in EU member countries after the product obtains marketing authorization, as well as streamlined regulatory review processes and registration and other fee reductions.
A new biological study by the University of Stirling has found that exposure to infections in early life does not have long-lasting consequences for later-life survival and reproduction.
PURE Bioscience announced that it has expanded its business strategy through an alliance with the Dallas-based sales and marketing team Richmont Sciences, LLC, which will begin actively selling PURE's revolutionary new antibacterial, antiviral and antifungal hard surface disinfectant and its active ingredient.
Investigators at Duke Medicine and the University of California, San Francisco have been selected to oversee a nationwide research program on antibacterial resistance, which includes a focus on the growing unmet challenges associated with methicillin-resistant Staphylococcus aureus and E. coli.
Spacelabs Healthcare is pleased to announce the U.S. launch of Sentinel, a sophisticated Cardiology Information Management Systems (CIMS), that will facilitate analysis and reporting while also improving efficiency and eliminating errors.
› Verified 3 days ago
Dr. Alvaro Andres Puig Rodriguez, M.D Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 1625 N George Mason Dr Ste 425, Arlington, VA 22205 Phone: 703-717-4400 | |
Tiffany C Turner, MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 1625 N George Mason Dr Ste 345, Arlington, VA 22205 Phone: 703-717-4400 Fax: 703-717-4401 | |
Dr. Anne Ruggles Pariser, MD Cardiovascular Disease Medicare: Not Enrolled in Medicare Practice Location: 2921 11th St S, Arlington, VA 22204 Phone: 703-979-1400 | |
Dr. Michael Andrew Cole, M.D. Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 1701 N George Mason Dr, Intensive Care Unit, Arlington, VA 22205 Phone: 571-244-8410 | |
Robert Paul Holman, MD Cardiovascular Disease Medicare: Medicare Enrolled Practice Location: 1635 N George Mason Dr, Suite 180, Arlington, VA 22205 Phone: 703-276-7798 Fax: 703-276-0433 | |
Dr. Irmindra S Rana, MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 611 S Carlin Springs Rd, Suite 301, Arlington, VA 22204 Phone: 703-998-0480 Fax: 703-379-0449 | |
Dr. Ashok Chauhan, M.D., Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 611 S Carlin Springs Rd, Suite 511, Arlington, VA 22204 Phone: 703-379-4446 Fax: 703-379-0449 |